CHO YONGJIN | Oncology | Best Researcher Award

Dr. CHO YONGJIN | Oncology | Best Researcher Award

Dept. of Orthopedic Surgery, at Chosun University Hospital, South Korea.

Dr. Yongjin Cho is an Associate Professor in the Department of Orthopaedic Surgery at Chosun University College of Medicine. With a rich academic and professional journey spanning over two decades, Dr. Cho specializes in orthopedic surgery, musculoskeletal oncology, and pediatric orthopedics. He is recognized for his innovative contributions to trauma and sarcoma management and has published extensively in high-impact journals. In addition to his clinical expertise, Dr. Cho is actively involved in medical robotics research, emphasizing its potential in surgical advancements. His dedication to education, research, and patient care highlights his standing as a distinguished professional in orthopedics.

Profile

Scopus

Education πŸŽ“

Dr. Cho’s academic background reflects his dedication to interdisciplinary excellence:

  • B.Eng. (Industrial Engineering) – Chonnam National University, 1995.
  • B.Med. (Medicine) – Chonnam National University, 2000.
  • M.Med. (Orthopaedics) – Chonnam National University, 2008.
  • Ph.D. (Medicine) – Chonnam National University, 2016.

His advanced training in both engineering and medicine has provided a unique perspective in integrating technology into clinical practice and research.

Professional Experience 🩺

Dr. Cho began his career as an orthopedic resident at Chonnam National University Hospital (2005–2009), later specializing in foot and ankle, hip, and pediatric orthopedics. He obtained his orthopedic specialty license in 2009. His roles include:

  • Fellowship Training in Foot and Ankle Surgery (2009).
  • Clinical Professor in Pediatric and Musculoskeletal Tumor Surgery (2010–2011).
  • Assistant Professor at Yonsei Severance Sinchon Hospital (2011–2015).
  • Associate Professor at Chosun University (2018–present).

Dr. Cho also serves as an Insurance Professional Committee Member for the Korea Musculoskeletal Oncologic Society.

Research Interests πŸ”¬

Dr. Cho’s research spans orthopedic oncology, trauma surgery, and medical robotics, with a focus on:

  • Innovative surgical techniques for sarcomas and musculoskeletal tumors.
  • Integration of robotics in orthopedic surgery.
  • Biomechanics and implant design for improved surgical outcomes.
  • Pediatric orthopedic deformities and treatments.
    His work emphasizes applying cutting-edge technologies, such as robotic systems, to enhance surgical precision and patient care.

Awards & Recognitions πŸ†

Dr. Cho has received numerous awards throughout his career, including:

  • Recognition for Excellence in Orthopedic Research from the Korean Orthopedic Association.
  • Contributions to musculoskeletal oncology recognized by the Korean Musculoskeletal Oncologic Society.
  • Awards for innovative research in medical robotics and its application in orthopedics.
    These accolades underscore his impact as a clinician, educator, and researcher.

Top Notes Publications πŸ“š

Dr. Cho has authored over 40 publications in reputable journals. Selected works include:

1.Oblique Supramalleolar Opening Wedge Osteotomy Without Fibular Osteotomy for Varus Deformity of the Ankle

  • Journal: Foot & Ankle International (2009)
  • Summary: This study focuses on a surgical technique for correcting varus deformity of the ankle without performing a fibular osteotomy. The oblique supramalleolar opening wedge osteotomy is highlighted as a less invasive method with reduced complications, maintaining joint alignment and functionality.
  • Key Findings:
    • Effective for varus ankle deformity correction.
    • Demonstrates reduced operative risks.
    • Enhances post-surgical outcomes with less recovery time.
  • Relevance: Important for orthopedic surgeons exploring minimally invasive techniques for lower extremity deformities.

2. Prognostic Implications of Polycomb Proteins in Sarcoma

  • Journal: BMC Cancer (2018)
  • Summary: This research evaluates the role of Polycomb group (PcG) proteins in the prognosis of sarcoma. It investigates the molecular pathways influenced by PcG proteins and their impact on tumor behavior, aggressiveness, and patient survival.
  • Key Findings:
    • Overexpression of PcG proteins correlates with poor prognosis in sarcoma.
    • PcG proteins influence tumor proliferation, migration, and resistance to therapy.
    • Provides a foundation for potential therapeutic targeting of PcG pathways.
  • Relevance: Crucial for oncology researchers and clinicians focusing on molecular biomarkers and targeted therapy for sarcoma.

3. HMB45-Negative Intramuscular Angiomyolipoma: A Case Report and Review

  • Journal: Bahrain Medical Bulletin (2021)
  • Summary: This case report describes a rare presentation of HMB45-negative intramuscular angiomyolipoma, providing diagnostic challenges and insights into its pathology. It reviews similar cases to outline management strategies for this unique subtype of angiomyolipoma.
  • Key Findings:
    • HMB45-negative cases present diagnostic difficulty due to the absence of a typical immunohistochemical marker.
    • Highlights the importance of morphological evaluation and differential diagnosis.
    • Discusses successful management options, including surgical resection.
  • Relevance: Valuable for pathologists and clinicians involved in diagnosing and managing rare soft tissue tumors.

4. Healthcare Robots in the New Normal Era

  • Journal: Journal of Digital Convergence (2021)
  • Summary: This article examines the growing role of healthcare robots in the β€œNew Normal” era, especially post-COVID-19. It explores their applications, benefits, and challenges in various healthcare settings.
  • Key Findings:
    • Robots enhance efficiency in patient care, disinfection, and remote monitoring.
    • Reduced human contact minimizes infection risks in pandemics.
    • Challenges include high costs, technical limitations, and ethical considerations.
  • Relevance: Pertinent for researchers and practitioners in health informatics, robotics, and digital transformation of healthcare systems.

Conclusion

Dr. Yongjin Cho is a highly qualified candidate for the Best Researcher Award. Their comprehensive experience in orthopaedic surgery, commitment to research innovation, and significant academic contributions make them an exemplary researcher. While areas like grant acquisition, international collaborations, and public engagement could be strengthened, their current achievements are commendable and worthy of recognition. Dr. Cho’s work has the potential to set new benchmarks in orthopaedic research and medical robotics, reflecting excellence in advancing both clinical and academic frontiers.

 

Chenjing Zhu | Oncology | Best Researcher Award

Dr. Chenjing Zhu | Oncology | Best Researcher Award

Associate professor, Jiangsu Cancer Hospital, China

Cenjing Zhu is a dedicated medical professional specializing in radiation oncology at Jiangsu Cancer Hospital, Nanjing, China. With a strong background in clinical research and cancer treatment, she has made significant contributions to understanding cancer biology and therapeutic strategies. Dr. Zhu has a keen interest in advancing medical science through research, education, and clinical excellence. πŸŒŸπŸ’‰

Publication Profile

ORCID

Education

Dr. Zhu completed her Bachelor of Medicine (2011-2016) and M.D. (2016-2019) from the West China School of Medicine, Sichuan University, Chengdu, China. Her academic journey in the field of medicine has paved the way for her expertise in oncology and cancer research. πŸŽ“πŸ“š

Experience

Since 2019, Dr. Zhu has been a part of the Department of Radiation Oncology at Jiangsu Cancer Hospital, where she contributes to both clinical care and scientific research. Her leadership in cancer research and clinical innovation is well-recognized within the medical community. πŸ₯πŸ’Ό

Research Focus

Dr. Zhu’s research primarily revolves around cancer therapeutics, focusing on the AXL receptor tyrosine kinase as an anti-cancer approach, psychological distress in cancer patients, and innovative diagnostic techniques in oncology. She is particularly interested in tumor microenvironment modulation and the application of advanced imaging techniques in cancer treatment. πŸ”¬πŸ§¬

Awards and Honors

Throughout her career, Dr. Zhu has been invited to present her work at prestigious international conferences, including the World Congress on Advances in Oncology and the International Symposium on Molecular Medicine. Her research excellence has garnered recognition and invitations to prominent platforms for cancer research and molecular medicine. πŸ†πŸŒ

Publication Top Notes

Zhu’s influential article on AXL receptor tyrosine kinase as a promising anti-cancer approach, Molecular Cancer 2019, has reshaped clinical strategies, cited extensively.

Her 2020 study on dual MET/AXL inhibitors in gastric carcinoma, published in MedComm, offers groundbreaking insights into tumor microenvironment modulation.

Zhu’s 2024 research in BMC Psychol on psychological distress in Chinese cancer patients demonstrates the importance of mental health during cancer treatment.

Her 2024 review of circulating microRNAs as diagnostic biomarkers for cervical cancer in Discov Oncol continues to shape diagnostic research in oncology